GeoVax Labs, Inc. senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco from January 12-15, 2026. During these forums, company leadership will review 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026, including key clinical catalysts, regulatory milestones, and business development initiatives. The presentation will cover multiple programs including CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. The company will discuss clinical status, translational data, and regulatory pathways for high-risk and immunocompromised populations.
For oncology, the company will present translational and clinical data supporting development of Gedeptin® in head and neck cancer and other solid tumor indications. GeoVax will also discuss regulatory progress, clinical strategy, and potential registration pathways for GEO-MVA, a vaccine targeting Mpox and smallpox that may progress directly to Phase 3 clinical evaluation based on recent EMA regulatory guidance. The company will highlight advancements in its manufacturing platform, specifically continuous cell-line manufacturing enabling scalable, resilient, and domestic vaccine production.
David Dodd, Chairman and CEO of GeoVax Labs, will present on January 13, 2026, at 2:30 pm PST at the Hilton Union Square in San Francisco. The presentation will be webcast live and may be accessed through the Events & Presentations section of the company's website at https://www.geovax.com. Management will also host one-on-one investor and partner meetings throughout the conference to discuss the company's progress across its diverse pipeline.
"We are pleased to share GeoVax's 2025 achievements with the global investor and biotech community at Biotech Showcase and the J.P. Morgan Healthcare Conference," said David Dodd. "Our team has delivered meaningful clinical and operational progress, strengthened our strategic position, and advanced multiple programs toward key inflection points in 2026." The company's presentation will focus on partnership and collaboration opportunities to support pipeline advancement and long-term value creation.
